LUNG cancer diagnosisLUNG cancer treatmentCANCER-related mortalityNON-small-cell lung carcinomaLung cancer is the most common cause of cancer-related deaths both in Poland and worldwide. Recently, the incidence of lung adenocarcinoma has been increasing and currently it accounts for about 45...
[7] Ando K, Manabe R, Kishino Y, et al. Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review...
[22] D’Antonio F,De Sanctis R,Bolengo I,et al.Pulmonary sarcomatoid carcinoma presenting both ALK rearrangement and PD⁃L1 high positivity:A case report on the therapeutic regimen[J].Medicine(Baltimore),2019,98(32):...
参考文献 [1]Zhang Chao, Li Shao-Lei, Nie Qiang, et al. Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement. J Thorac Oncol, 2019, 14: 726-731. [2]Zhang C, Jiang BY, Yan LX, et al. Induction ALK-TKIs for stage III non-small cell ...
ALK rearrangementALK-positive NSCLCCrizotinibCeritinibAlectinibResistance mechanismAnaplastic lymphoma kinase (ALK) rearrangement is detected in 3鈥 7% of patients with non-small-cell lung cancer. Crizotinib is an ALK inhibitor, which was approved in 2011 for the treatment of ALK-positive lung cancer. ...
[16] Ando K, Akimoto K, Sato H, et al. Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis[J]. Cancers (Basel). 2020;12(4):942. ...
9、Ando K, Manabe R, Kishino Y, et al. Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis. Cancers (Basel). 2021;13(15):3704. Published...
9、Ando K, Manabe R, Kishino Y, et al. Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis. Cancers (Basel). 2021;13(15):3704. Published...
ALK rearrangement is a very rare subset of squamous cell cancer of lung and the efficacy of crizotinib treatment for these patients is lack of data. Here we report a case with squamous cell cancer of lung that harbored the ALK rearrangement was given crizotinib in the second-line therapy. A...
Journal of Thoracic Oncology, 2020, 15: e95-e99. [14] Gu R, Shi Z, Duan T, et al. Feasibility and safety of neoadjuvant alectinib in pulmonary invasive mucinous adenocarcinoma with ALK rearrangement: case report and literature review[J]. OncoTargets and therapy, 2021: 5107-5113. 更多全部...